How much did the MHRA seize in 2025?

Almost £45 million of illegal medicines — nearly 20 million doses, including more than 5,000 illegally traded GLP-1 products.

Does the law target specific compounds?

No. The offence is supplying a medicinal product without authorisation, which depends on presentation and claimed purpose rather than the molecule.

Why did GLP-1 enforcement increase?

High demand for an expensive, supply-constrained licensed medicine creates the margin that makes unauthorised manufacture profitable.

Research & Regulatory News

The Scale of UK Medicines Enforcement

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-233 cited sources

The MHRA reported in January 2026 that it seized illegal medicines worth almost £45 million during 2025 — nearly 20 million doses in total, including more than 5,000 illegally traded GLP-1 products.

Key facts

Reported: 26 January 2026, gov.uk
Total value: Almost £45 million
Total doses: Almost 20 million
GLP-1 products: More than 5,000 illegally traded
Quoted: Andy Morling, Deputy Director, Enforcement
Related action: Northampton facility, October 2025

What the figures cover

All illegally traded medicines, not weight-loss products alone. Nearly 20 million doses across the year, valued at almost £45 million, which the agency described as more illegally traded medicine removed from circulation than in any previous year.

Where GLP-1 products sit within it

More than 5,000 illegally traded GLP-1 products. Against 20 million doses overall that is a small fraction by count and a highly disproportionate one by attention, cost and clinical risk — these are injectables with no verified contents, sold into a market with extraordinary demand.

Research material referenced

Retatrutide 10mg — third-party HPLC tested

View — £59.99

Why enforcement scaled up when it did

Demand created margin. When a licensed medicine is expensive, supply-constrained and desired by very large numbers of people, the incentive to manufacture and sell unauthorised versions rises accordingly. The Northampton facility dismantled in October 2025 is what that incentive produces at industrial scale.

What the agency said

Andy Morling, Deputy Director for Enforcement, was quoted saying that working with law enforcement partners the agency had removed more illegally traded medicines from circulation than ever before, and urging people to think very carefully before buying powerful medicines online.

How the framework decides what is illegal

Not the molecule. Supplying a medicinal product without authorisation is the offence, and what makes something a medicinal product includes how it is presented and what it is offered for. A compound supplied as unformulated laboratory material with no therapeutic claim sits outside that; the same compound in a labelled pen sold for injection does not.

What this means for how this site is written

Every article here reports what published research measured and in which model or population. None claims that any compound treats, prevents or improves anything in any person, and none provides dosing or administration guidance. That is a deliberate response to exactly the framework these enforcement figures describe.

Extended research context

The Research & Regulatory News deep dive

Deep dive: why 2026 was the year the incretin field split in two

For a decade every meaningful GLP-1 medicine was a peptide, and every one of them was injected. 2026 broke that pattern in both directions at once. In August the MHRA authorised orforglipron, a small molecule with no peptide bonds that works as an ordinary daily tablet. Three months earlier, retatrutide's TRIUMPH-1 reported a 28.3% mean weight reduction — the largest figure yet from a single molecule, and achievable only with a peptide capable of engaging three receptors at once. The field is not converging on one answer; it is separating into a convenience track and a magnitude track, and those tracks have different chemistry.

Deep dive: what a marketing authorisation actually means

An authorisation is granted to a specific product, in a specific formulation, for a specific indication, by a specific regulator. It is not a statement about a compound class and it does not transfer. Orforglipron being licensed in the UK tells you nothing about the legal or regulatory status of any other incretin, and nothing at all about compounds that remain investigational. Authorisation is also separate from funding: a licensed medicine is not automatically available on the NHS, which requires a further NICE appraisal.

Deep dive: reading trial results without being misled

Headline percentages are the least transferable part of a trial. A figure is only meaningful alongside its population, its duration, its comparator and its dropout rate. TRIUMPH-1's 28.3% came from an 80-week study in a relatively uncomplicated obesity population; TRIUMPH-3's 22.6% came from adults with severe obesity and established cardiovascular disease, and the gap between those two numbers is mostly population, not potency. Discontinuation rates deserve the same attention as efficacy: 11.3% of the TRIUMPH-1 12 mg arm stopped due to adverse events against 4.9% on placebo, and that figure is routinely dropped from summaries.

Research applications

▸Tracking regulatory status of investigational incretin compounds
▸Understanding the difference between authorisation, NICE appraisal and NHS availability
▸Comparing peptide and non-peptide receptor agonist pharmacology
▸Interpreting Phase 3 topline releases before peer-reviewed publication
▸Verifying trial identity against ClinicalTrials.gov registrations

Handling checklist

✓Check the compound named in a trial registration matches the compound being discussed
✓Confirm the NCT identifier resolves to the acronym being cited
✓Read topline press releases as preliminary until peer-reviewed publication
✓Separate the trial population from the headline percentage before comparing studies
✓Treat authorisation in one jurisdiction as saying nothing about status in another

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Treating a positive Phase 3 as approval

Fix: Filing begins a review that commonly takes a year or more and can end in a request for more data.

✗ Comparing weight-reduction percentages across different trials

Fix: Population, duration and comparator differ; the numbers are not interchangeable.

✗ Assuming one incretin's approval legitimises another compound

Fix: Authorisations are product-specific and do not transfer between compounds.

✗ Citing a TRIUMPH number without checking the NCT identifier

Fix: Verify against ClinicalTrials.gov — the numbering has been widely misreported.

✗ Reading research material as an alternative to a licensed medicine

Fix: Research material is supplied for laboratory use only and is not a substitute for anything prescribed.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

How much did the MHRA seize in 2025?: Almost £45 million of illegal medicines — nearly 20 million doses, including more than 5,000 illegally traded GLP-1 products.
Does the law target specific compounds?: No. The offence is supplying a medicinal product without authorisation, which depends on presentation and claimed purpose rather than the molecule.
Why did GLP-1 enforcement increase?: High demand for an expensive, supply-constrained licensed medicine creates the margin that makes unauthorised manufacture profitable.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More Research & Regulatory News articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum